CClinicalTrials.gg
CompletedNCT03750305Updated Aug 31, 2021

Evaluating the Effectiveness of Imagery Focussed Therapy

An interventional study of imagery-focused Cognitive Therapy and TAU in Bipolar Disorder, sponsored by Maastricht University. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2021-08-31.

Sponsored by Maastricht University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 68 Years
Sex
All
01

Study summary

This study explores the effectiveness of a brief Imagery-focussed Cognitive Therapy (imCT) compared to psychoeducation, regarded as treatment as usual for this patient population, in patients suffering from BD receiving mood stabilising medication. ImCT was successfully tested in a pilot study using a case series design. The investigators now elaborate on this study comparing effectiveness of the intervention to psychoeducation/TAU.

Read the detailed description

Bipolar disorder (BD) is a severe mental health illness affecting 1.9% to 2.4% of the population and is associated with high inter episode distress, ongoing mood swings (mood variability), high suicide risks and high co-morbidity (especially anxiety). 50% of patients do not recover within one year, and only 25% of patients achieve full recovery of function, despite receiving the recommended lead intervention consisting of pharmacotherapy (mood stabilisers such as lithium). Added psychoeducation and cognitive behavioural interventions (CBT) have only modest effects. Overall there is consensus for the need to update CBT and increase its effectiveness, aimed at not only managing symptoms but also targeting perpetuating or precipitating factors influencing symptoms, especially mood variability.

Recent studies suggest that patients with BD experience more vivid, compelling and upsetting mental images compared to patients suffering from unipolar depression and healthy controls and that this may contribute to or even maintain their clinical difficulties. That is, imagery in experimental research has proven to have a stronger effect on mood changes than verbal cognitions. The amplified imagery vividness of patients suffering from BD might therefore precipitate or perpetuate their mood variability. In many other mental health problems imagery interventions as a stand-alone intervention, or added to regular CBT, are offered with the aim to decrease imagery vividness or modify/update appraisals of imagery. In BD patients such interventions, therefore, might also target important precipitating or perpetuating factors influencing their mood problems.

This study aims to assess the effectiveness of a brief Imagery-focussed Cognitive Therapy (imCT) compared to psychoeducation, regarded as treatment as usual for this patient population, in patients suffering from BD receiving mood stabilising medication. ImCT was successfully tested in a pilot study using a case series design. The investigators now elaborate on this study comparing effectiveness of the intervention to psychoeducation/TAU. The investigators hypothesise that (1a) mood variability (primary outcome variable) and (1b) symptoms of depression, mania and anxiety (secondary outcome variables) show stronger decreases in BD patients receiving imCT than in patients receiving psychoeducation/TAU. Moreover, (2) in the imCT group this effect is expected to be mediated by changes in imagery which is targeted during this intervention (target imagery). The investigators also hypothese that (3) imagery frequency and compellingness and vividness of imagery reduce more in the imCT group than in the group receiving psychoeducation/TAU. The primary outcome variable, mood variability, is calculated using daily mood measurements, during a 4-week baseline, during the invention and after the end of intervention until follow up at 16 weeks, in both imCT and psychoeducation/TAU. Most secondary outcome variables are assessed using weekly online questionnaires, pre-and post intervention and at 8 and 16 weeks follow-up, anxiety is calculated both weekly online and using daily measurements (see below).

02

Conditions studied

  • Bipolar Disorder

Browse trials for

03

In context

Bipolar Disorder

1,601 studies on the registry are indexed under Bipolar Disorder; 254 are open to participants now.

This study's enrollment of 62 is close to the median of 64 across 1,223 interventional studies indexed under Bipolar Disorder.

Browse Bipolar Disorder studies →

Lead sponsor

Maastricht University is the lead sponsor of 96 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 18-68
  • Sufficient Dutch language ability to permit the assessment to be completed.
  • Diagnosis of DB (I or II or NOS) according to DSM-5 (clinicians assessment).
  • Willing to complete daily and weekly monitoring throughout the duration of the study.
  • Successful completion of the daily monitoring in the 4 weeks active run-in phase.
  • Willing to be randomised to either imCT or psychoeducation/TAU condition
  • Can commit to attending 12 consecutive weekly sessions imCT or psychoeducation/TAU.

Exclusion criteria

Exclusion Criteria:

  • Learning difficulties, organic brain disease or severe neurological impairment.
  • Current severe substance or alcohol misuse (clinicians assessment).
  • Current manic episode as diagnosed by DSM-5
  • Current active psychotic symptoms
  • Presence of active suicidal risk as indicated by a score of 2 or more on item 12 (i.e. frequent thought and/or plans to end their life) of the QIDS (Rush et al., 2003) confirmed by convergent clinical opinion.
  • Taking part in concurrent treatment studies investigating pharmacological or psychological treatment for BD.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    psychoeducation/TAU

    TAU consists of psycho-education for a period of 12 weeks, consisting of 6 2-hour sessions. Psycho-education is offered in groups,

    Other: TAU

  • Experimental
    imCT intervention

    For a period of 12 weeks, 12 1-hour sessions of imagery-focused Cognitive Therapy delivered weekly by a trained therapists, divided in an in depth identification (4 sessions) of images followed by imagery interventions, (6 sessions) and a consolidation phase (2 sessions).

    Other: imagery-focused Cognitive Therapy

Interventions

  • Otherimagery-focused Cognitive Therapy

    In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus. Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these). Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary.

    Also known as: ImCT

  • OtherTAU

    Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, \& van Gent, 2008).

    Also known as: Psychoeducation

06

What researchers measure

Primary outcomes

  1. Change from baseline Mood variability to follow up at 16 weeks after end of intervention

    Mood variability is measured using the Affect Lability Score Short Version (ALS-18; Oliver \& Simons, 2004). The ALS-18 is a self-report scale measuring lability in affect and consists of 18 items. Ratings are made on a 4-point scale with a maximum score of 72. Scores range from A= very characteristic of me (4 points), to D= very uncharacteristic of me (1 point).

    Time frame: The ALS-18 is administered at T0, after 4 weeks baseline at T1, after the end of intervention (12 weeks in the ImCT condition, and 6 weeks in the psychoeducation condition) T2, 8 weeks after the end of intervention T3, and after 16 weeks follow up -T4.

Secondary outcomes

  1. Change from baseline Level of depression to follow up at to follow up at 16 weeks

    - Level of depression, using the Quick Inventory of Depressive Symptoms (QIDS-SR) (Rush et al., 2003). The QIDS-SR is a 16-item self-report rating scale in which the nine DSM 5 symptoms of major depression are incorporated. Answers are rated on a four-point Likert scale (0-3).

    Time frame: measured weekly throughout the duration of the study in both groups (32 weeks imCT and 26 weeks psychoeducation/TAU).

  2. Change from baseline level of mania to follow up at 16 weeks

    - Level of mania, using the Altman Self-Rating Mania Scale (ASRM-NL) (Altman, Hedekker, \& Peterson, 1997). The ASRM-NL is a 5 item self-report instrument to measure severity of mania symptoms. Answers are rated on a 5-point Likert scale, where higher scores indicate higher levels of mania. Total score ranges from 0 to 20, with a cut off score of 5 or more indicating relapse into mania.

    Time frame: measured weekly throughout the duration of the study in both groups ( 32 weeks imCT and 26 weekspsychoeducation/TAU).

  3. Change from baseline level of anxiety to follow up at 16 weeks

    - Level of anxiety, using the Beck Anxiety Inventory (BAI) (Osman, Barrios, Aukes, Osman, \& Markway, 1993). The BAI is a 21-item self-report questionnaire used for measuring the severity of anxiety. Answers are rated on a 4-point Likert scale (0-3). Total scores range from o to 63, where scores of 22 or more indicate moderate anxiety, 36 or more concerning levels of anxiety.

    Time frame: measured both daily and weekly throughout the duration of the study in both groups (32 weeks imCT and 26 weeks psychoeducation/TAU)

  4. Change from baseline level of hopelessness to follow up at 16 weeks follow up

    participants rate their hopelessness using the Beck Hopelessness Scale (Beck, Brown, \& Steer, 1997), The BHS is a 20 item self-report scale measuring three aspects of hopelessness: feelings about the future, motivation and expectations. The BHS demonstrates good internal consistency (alpha = .93) and has high reliability in psychiatric samples (Beck et al., 1997)

    Time frame: measured at baseline (T0), after 4 weeks pre-intervention (T1), post-intervention after 6 weeks in the psychoeduc condition and 12 weeks in the ImCT condition (T2) and at follow up at 8 weeks (T3) and at 16 weeks (T4).

  5. Change from baseline level of general functioning and coping to follow up at 16 weeks

    Participants rate their level of functioning using the Longitudinal Interval Follow up Evaluation - Range of Impaired Functioning Tool (Leon, et al., 1999). This is a brief scale for people suffering from affective disorders, measuring four different functional areas (employment, interpersonal relations, satisfaction and recreation) on a 5 point Likert scale (low rating imply higher functioning).

    Time frame: Participants rate their level of functioning at baseline (T0), after 4 weeks pre-intervention (T1), post-intervention12 weeks in the ImCT condition and 6 weeks in the psychoeducation condition (T2) and at follow up at 8 weeks (T3) and at 16 weeks (T4).

  6. Change from baseline level of mood variability to follow up at 16 weeks

    Mood variability, using daily measurements of both mania and depression with the National Institute of Mental Health Life Chart Methodology (NIMH-LCM) Prospective Self-Rating (Denicoff et al., 2000; Leverich and Post, 1998). Participants rate their mood (both mania and depression) on a 11-point likert scale, ranging from -4 (severe depression, admission required due to severe dysfunction) to 0 (stable mood) to +4 (severe mania, admission required due to severe dysfunction).

    Time frame: Daily measurements throughout the duration of the study, 32 weeks for the participants in the ImCT condition and 26 weeks for the participants in the psychoeducation condition

  7. Change from baseline level of anxiety to follow up at 16 weeks

    Anxiety is measured on a VAS scale indicating no anxiety (1) to severe anxiety (4).

    Time frame: Daily measurements throughout the duration of the study, 32 weeks for the participants in the ImCT condition and 26 weeks for the participants in the psychoeducation condition

Other outcomes

  1. General Imagery (frequency of imagery, quality of imagery and appraisals of imagery):

    This measured using a 42-item online Imagery Survey recently validated in a student sample, and presently used in an on-going current study comparing imagery aspects between patients suffering from BD, patients suffering from unipolar depression and imagery prone students without a present disorder. This is further assessed using the Mental Imagery and Coping with Bipolar Disorder Questionnaire (MICQ-BD) is a 14 item self-report instrument assessing patient's response to mental imagery on a five-point Likert scale, ranging from "not at all" to "a lot". In a pilot study Holmes (2016) calculated the internal conconsistency (alpha = .70) of this measure to be satisfactory (DiSimplicio et al., 2016).

    Time frame: administered at T0, after 4 weeks baseline at T1, after the end of intervention (12 weeks in the ImCT condition, and 6 weeks in the psychoeducation condition) T2, 8 weeks after the end of intervention T3, and after 16 weeks follow up -T4.

  2. Ratings of target imagery (moderator)

    Changes in target imagery are measured in order to test if reductions in moodvariablity compared to baseline (i.e. the primary objective) are mediated by reductions in levels of problematic imagery during treatment. The Visual Analogue Scales of Imagery Characteristics (VAS Imagery) have been tailored to BD population rating on a scale 0-9, for example such as: "How real / vivid / absorbing / preoccupying / compelling have your image(s) been over the past week'"; "To which extent could you understand the role that the image(s) play in your mood instability?"; "To which extent could you find positive / helpful way of using the image(s)?". Target imagery is measured weekly throughout the duration of the study in the imCT group.

    Time frame: Measured weekly throughout the study for 32 weeks in the ImCT condition and 26 weeks in the psychoeducation condition

  3. General Imagery

    Changes in general imagery are measured using the Mental Imagery and Coping with Bipolar Disorder Questionnaire (MICQ-BD) is a 14 item self-report instrument assessing patient's response to mental imagery on a five-point Likert scale, ranging from "not at all" to "a lot". In a pilot study Holmes (2016) calculated the internal conconsistency (alpha = .70) of this measure to be satisfactory (DiSimplicio et al., 2016).

    Time frame: administered at T0, after 4 weeks baseline at T1, after the end of intervention (12 weeks in the ImCT condition, and 6 weeks in the psychoeducation condition) T2, 8 weeks after the end of intervention T3, and after 16 weeks follow up -T4.

07

Study locations

1 site
  • Centrum Bipolair, GGzE
    Eindhoven, Netherlands
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 31, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03750305
Lead sponsor
Maastricht University
Responsible party
Karin van den Berg (Clinical Psychologist, PhD student Maastricht University, Maastricht University) — Principal investigator
First posted
Nov 23, 2018
Start date
Oct 1, 2018
Primary completion
Dec 30, 2020
Completion
Dec 30, 2020
Last update
Aug 31, 2021

Study contacts

karin van den Berg
principal investigator · Maastricht University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion